ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR)
July 07 2022 - 6:32AM
Business Wire
Webinar Featuring Dr. Charles Brenner
ChromaDex Corp. (NASDAQ:CDXC) today announced that it will host
a key opinion leader (KOL) webinar on the transforming benefits of
nicotinamide riboside (NR) on Wednesday, July 20, 2022 at 11:00 am
Eastern Time.
The webinar will feature a presentation from KOL and discoverer
of the vitamin activity of NR, Dr. Charles Brenner, Alfred E Mann
Family Foundation Chair in Diabetes and Cancer Metabolism at City
of Hope National Medical Center and ChromaDex Chief Scientific
Advisor, who will discuss the latest research on NR and its many
benefits as a precursor to nicotinamide adenine dinucleotide
(NAD+). NAD+ is the central catalyst to multiple metabolic
processes and a critical ally to cellular resilience and repair in
healthy aging.
ChromaDex’s consumer supplement, Tru Niagen®, which features the
company’s proprietary ingredient Niagen®, patented NR, will be
discussed as the market’s most scientifically supported way to
boost NAD+. Additionally, ChromaDex’s President & CEO, Rob
Fried, will provide a company update.
A live question and answer session will follow. The event is
open to the public and to register, please click here.
About Dr. Charles Brenner:
Dr. Charles Brenner, is one of the world’s leading experts on
nicotinamide adenine dinucleotide (NAD), the central catalyst of
metabolism, and the discoverer of the vitamin activity of
nicotinamide riboside (NR). Dr. Brenner is a 1983 graduate of
Wesleyan University who worked for five years in industry (Chiron
Corporation and DNAX Research Institute) prior to earning his 1993
PhD in Cancer Biology in the Biochemistry Department of Stanford
University. He then served as a Leukemia Society of America Fellow
at Brandeis University. Dr. Brenner has been an independent and
externally funded investigator for 26 years, having served on the
faculty of Thomas Jefferson University (1996-2003), Dartmouth
College (2003-2009), University of Iowa (2009-2020), where he was
the Roy J. Carver Chair and Head of the Biochemistry Department and
the Beckman Research Institute of City of Hope (2020-present),
where he is the inaugural Alfred E. Mann Chair of the Department of
Diabetes & Cancer Metabolism. Brenner has won numerous awards
for his research including new investigator awards from the March
of Dimes, the Burroughs Wellcome Trust, the Arnold & Mabel
Beckman Foundation, research awards from the NIH, the NSF, Lung
Cancer Research Foundation and the Gates Foundation, and
prestigious lectureships or honors from the University of Michigan,
Brown University, University of Nebraska, the Spanish National
Cancer Institute, the American Society for Biochemistry and
Molecular Biology and the American Society of Nutrition. His work
on NR was licensed and developed into the Tru Niagen consumer
product by ChromaDex, a company for which he serves as the chief
scientific advisor. He is globally in demand to educate people
about NAD, having lectured all over North and Central America,
Europe, the Middle East, the Far East and Oceana. His laboratory
continues to work on unsolved problems in metabolism as they relate
to virology, women’s and children’s health, cancer, chronic and
degenerative conditions, and rare diseases. When he is not doing
science or teaching about NAD, he can be found exercising or
gardening in Pasadena, California.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to whether Niagen® is the
market’s most scientifically supported way to boost NAD+ and
whether NAD is the central catalyst to multiple metabolic processes
and a critical ally to cellular resilience and repair in healthy
aging. Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,"
"possible," "probable," "believes," "seeks," "may," "will,"
"should," "could" or the negative of such terms or other similar
expressions. Risks that contribute to the uncertain nature of these
forward-looking statements include the impact of the COVID-19
pandemic on our business and the global economy; our history of
operating losses and need to obtain additional financing; the
growth and profitability of our product sales; our ability to
maintain sales, marketing and distribution capabilities; changing
consumer perceptions of our products; our reliance on a single or
limited number of third-party suppliers; and the risks and
uncertainties associated with our business and financial condition.
More detailed information about ChromaDex and the risk factors that
may affect the realization of forward-looking statements is set
forth in ChromaDex's Annual Report on Form 10-K for the fiscal year
ended December 31, 2021, ChromaDex's Quarterly Reports on Form 10-Q
and other filings submitted by ChromaDex to the SEC, copies of
which may be obtained from the SEC's website at www.sec.gov.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and actual results may differ materially from those suggested by
these forward-looking statements. All forward-looking statements
are qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220707005138/en/
ChromaDex Media Contact: Kendall Knysch, Director of
Media Relations 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of Finance and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024